High specificity
Induction of tolerance to our own myelin antigens
Innovative therapeutic vaccine XEMYS™ for the treatment of multiple sclerosis
Innovative therapeutic vaccine XEMYS™ for the treatment of multiple sclerosis
XEMYS™ was created on the base of a number of fundamental discoveries related to how autoreactive lymphocytes (including B-cells) behave in the course of multiple sclerosis.
The mechanism of action of the drug consists of a biphasic Th1-Th2 shift and further induction of T-regulatory cells. The drug contains immunodominant peptides of basic myelin protein, encapsulated in small mannosylated liposomes, and has successfully passed two phases of clinical trials.
THE BENEFITS OF XEMYS™
High specificity
Induction of tolerance to our own myelin antigens
Safety
Effectiveness
Stabilization of the condition in patients with previously non-coupable
Cost
It is expected, that XEMYS™ will be cheaper than existing drugs for multiple sclerosis therapy due to the perfection of its production technology
High specificity
Induction of tolerance to our own myelin antigens
Safety
Virtually no presence of side effects
Effectiveness
Stabilization of the condition in patients with previously non-coupable
Cost
It is expected, that XEMYS™ will be cheaper than existing drugs for multiple sclerosis therapy due to the perfection of its production technology
Was created by scientists of the Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences in cooperation with Pharmsynthez PJSC and Xenetic Biosciences, Inc.
The Shemyakin & Ovchinnikov Institute of bioorganic chemistry (IBCh) of the Russian Academy of Sciences is one of the largest Russian scientific organizations. The Institute is a leader in fundamental and innovative researches on the fields of molecular, structural and cell biology, bioorganic chemistry, biophysics, bioengineering, cell technologies, “in vivo” molecular based bioimaging, genome editing, bioinformatics etc. This multidisciplinary structure allows large-scale research at the interface of sciences, where the most interesting scientific discoveries are born today.
The hallmark of the IBCh RAS is the concentration of efforts and resources on solving the most urgent and complicated problems on the field of life sciences. Talented young people and leading specialists, including Russian and foreign science leaders, Nobel Prize laureates and members of the international advisory council of the Institute are involved in.
PUBLICATIONS